Antibodies directed against CD30 ligand
US5677430A · kind A · utility
11Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 12, 1995 |
| Grant date | Oct 14, 1997 |
| Priority date | — |
| Expiry date | Dec 12, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.